Endoscopic sleeve gastroplasty for obesity treatment

An Open-label, Randomized, Controlled Clinical Trial on the Effects of Endoscopic Sleeve Gastroplasty on Weight, Metabolic Risk Factors, Quality of Life, Satiety, Gastrointestinal Motility and Gut Microbiota

NA · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT04200144

This study is testing if a new procedure called endoscopic sleeve gastroplasty can help people with obesity lose weight and improve their health better than standard treatments.

Quick facts

PhaseNA
Study typeInterventional
Enrollment60 (estimated)
Ages20 Years to 65 Years
SexAll
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS (other)
Locations1 site (Rome)
Trial IDNCT04200144 on ClinicalTrials.gov

What this trial studies

This interventional trial compares the effects of endoscopic sleeve gastroplasty (ESG) on weight loss and metabolic health against standard medical therapy in individuals with obesity. Participants will be randomly assigned to either the ESG group or the control group, with follow-up assessments over 36 months. The study aims to evaluate various outcomes, including body weight loss, metabolic risk factors, quality of life, and changes in gut microbiota. Those in the control group may receive ESG after 6 months if they do not achieve satisfactory weight loss.

Who should consider this trial

Good fit: Ideal candidates are adults aged 20 to 65 with a BMI between 30 to 45 kg/m2 who are willing to comply with the study protocol.

Not a fit: Patients with active gastric ulcers, previous bariatric surgeries, or certain medical conditions such as uncontrolled thyroid disease or ongoing malignancies may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could provide a minimally invasive option for significant weight loss and improved metabolic health in obese patients.

How similar studies have performed: Previous studies have shown promising results with endoscopic procedures for obesity, indicating potential success for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

The participants have to fulfill the following criteria for participating in the study:

* Age 20 to 65 years
* BMI between 30 to 45 kg/m2
* Willingness to participate in the study and ability to comply and understand the study protocol

Exclusion Criteria:

Active gastric ulcer during the last 6 months

* Organic or motility disorder of the stomach and / or esophagus
* Anticoagulant treatment
* Previous bariatric surgery or any other type of surgery of the esophagus, stomach and duodenum
* Ongoing or active malignancy during the last 5 years
* Myocardial infarction during the past 6 months or/and heart failure class III or IV according to the New York Heart association's classification
* Drug or alcohol abuse
* Bulimic or binge eating pattern
* Continuous glucocorticoid or anti-inflammatory treatment
* Uncontrolled thyroid disease
* Pregnancy, breastfeeding
* Psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study
* Hiatal hernia \> 5 cm
* Currently participating in other study
* Any health issue that might put the patient at risk if the treatment is performed, judged by the investigator

Where this trial is running

Rome

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Obesity, Endoscopic Sleeve Gastroplasty, Gastric Motility, Gastric Hormones, Microbiota, Quality of Life

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.